Visualization of human T lymphocyte-mediated eradication of cancer cells in vivo
- 28 August 2020
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 117 (37), 22910-22919
- https://doi.org/10.1073/pnas.2009092117
Abstract
Lymphocyte-based immunotherapy has emerged as a breakthrough in cancer therapy for both hematologic and solid malignancies. In a subpopulation of cancer patients, this powerful therapeutic modality converts malignancy to clinically manageable disease. However, the T cell- and chimeric antigen receptor T (CAR-T) cell-mediated antimetastatic activity, especially their impacts on microscopic metastatic lesions, has not yet been investigated. Here we report a living zebrafish model that allows us to visualize the metastatic cancer cell killing effect by tumor- infiltrating lymphocytes (TILs) and CAR-T cells in vivo at the single-cell level. In a freshly isolated primary human melanoma, specific TILs effectively eliminated metastatic cancer cells in the living body. This potent metastasis-eradicating effect was validated using a human lymphoma model with CAR-T cells. Furthermore, cancer-associated fibroblasts protected metastatic cancer cells from T cell-mediated killing. Our data provide an in vivo platform to validate antimetastatic effects by human T cell-mediated immunotherapy. This unique technology may serve as a precision medicine platform for assessing anticancer effects of cellular immunotherapy in vivo before administration to human cancer patients.Funding Information
- European Research Council Advanced Grant (250021)
This publication has 39 references indexed in Scilit:
- Propranolol exhibits activity against hemangiomas independent of beta blockadenpj Precision Oncology, 2019
- Putting the Immunologic Brakes on CancerCell, 2018
- A Milestone for CAR T CellsThe New England Journal of Medicine, 2017
- Tragedy, Perseverance, and Chance — The Story of CAR-T TherapyThe New England Journal of Medicine, 2017
- Targeting the duality of cancernpj Precision Oncology, 2017
- The Principles of Engineering Immune Cells to Treat CancerCell, 2017
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's LymphomaThe New England Journal of Medicine, 2015
- Genetic Basis for Clinical Response to CTLA-4 Blockade in MelanomaThe New England Journal of Medicine, 2014
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigensNature, 2014
- Tumor Immunotherapy Directed at PD-1The New England Journal of Medicine, 2012